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O B J E C T I V E S This study sought to evaluate performance characteristics of routine echo for left
ventricular thrombus (LVT).
B A C KG ROUND Although the utility of dedicated echocardiography (echo) for LVT is established, echo
is widely used as a general test for which LVT is rarely the primary indication. We used delayed-enhancement
cardiac magnetic resonance (DE-CMR) as a reference to evaluate LVT detection by routine echo.
METHOD S Dedicated LVT assessment using DE-CMR was prospectively performed in patients with
left ventricular systolic dysfunction. Echoes were done as part of routine clinical care. Echo and CMR were
independently read for LVT and related indexes of LVT size, shape, and image quality/diagnostic
conﬁdence. Follow-up was done for embolic events and pathology validation of LVT.
R E S U L T S In this study, 243 patients had routine clinical echo and dedicated CMR within 1 week without
intervening events. Follow-up supported DE-CMR as a reference standard, with 5-fold difference in endpoints
between patients with versus without LVT by DE-CMR (p  0.02). LVT prevalence was 10% by DE-CMR. Echo
contrast was used in 4% of patients. Echo sensitivity and speciﬁcity were 33% and 91%, with positive and negative
predictive values of 29% and 93%. Among patients with possible LVT as the clinical indication for echo, sensitivity
and positive predictive value were markedly higher (60%, 75%). Regarding sensitivity, echo performance related
to LVT morphology and mirrored cine-CMR, with protuberant thrombus typically missed when small (p 0.02).
Therewas also a strong trend tomissmural thrombus irrespective of size (p 0.06). Concerningpositive predictive
value, echoperformance related to imagequality, with lower diagnostic conﬁdence scores for echoes readpositive
for LVT in discordance with DE-CMR compared with echoes concordant with DE-CMR (p  0.02).
CONC L U S I O N S Routine echo with rare contrast use can yield misleading results concerning LVT. Echo
performance is improved when large protuberant thrombus is present and when the clinical indication is
speciﬁcally for LVT assessment. (J Am Coll Cardiol Img 2011;4:702–12) © 2011 by the American College of
Cardiology Foundation
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703n clinical practice, echocardiography (echo) is
widely accepted as the primary screening test for
left ventricular thrombus (LVT) (1,2). This ap-
proach is supported by multiple studies showing
that echo performs well as a test for LVT when
imaging is tailored for this purpose (3–5). More
recently, sonographic contrast has been shown to
further improve diagnosis of LVT (6,7). Indeed,
prior research by our group and others has demon-
strated that a routine strategy of echo contrast use in
at-risk patients can markedly improve LVT assess-
ment, reducing both false positives and false nega-
tives (8,9).
See page 713
While the utility of dedicated echo for LVT is
established, echo is widely performed as a general
screening test of cardiac structure and function for
which thrombus is rarely the primary indication
(10). Echo contrast use also remains low (11),
possibly attributable to recent U.S. Food and Drug
Administration–mandated product safety label
warnings (12) and resultant controversy surround-
ing widespread use (11,13,14). Thus, for many
patients at risk for LVT, such as those with systolic
dysfunction, both the primary indication and the
use of echo contrast for LVT is rare. As echo is the
most common imaging test in the United States
(15), better understanding of its performance char-
acteristics in a real-life clinical setting is of substan-
tial importance.
Delayed enhancement (DE) cardiac magnetic
resonance (CMR) can establish LVT based on
avascular tissue characteristics, an approach that has
been shown to be highly accurate in multiple
validation studies (8,16–18). As DE-CMR is non-
invasive, it holds the added utility of studying LVT
in broad at-risk populations for whom an invasive
standard such as surgical pathology would be im-
practical. To date, DE-CMR has not been used to
study factors that influence performance of routine
clinical echo for detection of LVT.
We have previously reported the results of a
prospective registry in which patients with left
ventricular (LV) dysfunction underwent dedicated
CMR thrombus imaging and were thereafter fol-
lowed for prognostic assessment (18). In this prior
study, only cine- and DE-CMR were compared
and echo was not part of the research protocol. For
the current study, we evaluated registry patients in
whom echo was performed as part of clinical care.
The goal was to employ DE-CMR as a means to Linvestigate real-life practice patterns and perfor-
mance characteristics of routine echo for LVT.
M E T H O D S
Population. The study population was accrued from
n ongoing CMR registry of consecutive patients at
uke University with LV systolic dysfunction. The
ole criterion for registry participation was impaired
ystolic function, defined as a left ventricular ejec-
ion fraction (LVEF) below 50% measured quanti-
atively on cine-CMR. No patients were excluded
ased on clinical characteristics or other criteria. As
reviously reported (18), the CMR imaging proto-
ol entailed tailored (cine and DE) imaging for
edicated LVT assessment. Comprehensive clinical
ata was collected at the time of CMR, including
oronary risk factors, revascularization history, and
edication regimen. Echocardiography was not a
omponent of the registry protocol.
For the current study, clinical records
ere queried for all registry patients who
nderwent echo within 1 week of CMR.
cho was performed as part of routine
are at the discretion of treating clinicians.
o standardize interpretation of thrombus
nd assess imaging factors that could po-
entially influence echo performance,
choes were retrieved from image archives
nd interpreted for the express purpose of
his study by experienced (American
eart Association/American College of
ardiology level III) readers blinded to
atient identifiers or CMR results. Echoes
ere also reviewed for factors that could
otentially influence performance characteristics,
ncluding sonographic contrast use and clinical
ndication for echo.
In accordance with the established registry pro-
ocol (18), prospective follow-up was performed for
ndpoints consistent with presence or absence of
hrombus by imaging. For the current investigation,
ollow-up was examined in the subcohort of registry
atients that underwent CMR and echo. The
ollow-up protocol consisted of two components:
irst, all records were carefully reviewed in patients
ho had direct inspection and pathology evaluation
f the LV (i.e., patients who underwent heart
ransplantation, LV aneurysmectomy, or necropsy)
ithin 6 months of imaging. Second, follow-up was
erformed for identification of clinical embolic
vents that were highly suggestive of the presence of
A B B
A N D
CMR
reson
CVA
DE
echo
LV
ventri
LVEF
fractio
LVT
TI i
TIAVT. These events consisted of a documR E V I A T I O N S
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cardiac magnetic
ance
cerebrovascular accident
delayed enhancement
 echocardiography
left ventricle/left
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704cerebrovascular accident (CVA) or transient isch-
emic attack (TIA) that occurred within 6 months of
imaging. Concordant with established criteria
(19,20), CVA was defined as an acute neurologic
deficit of presumed vascular origin lasting 24 h,
nd TIA a deficit lasting 24 h. Clinical informa-
ion was obtained via: 1) telephone interview with
he patient, or, if deceased, with family members; 2)
ontact with the patient’s physician; and 3) hospital
ecords. All reported clinical events (CVA, TIA)
ere confirmed based on medical documentation by
treating physician. Death was not considered
vidence of LVT unless attributed to a cerebrovas-
ular embolic event.
This study was performed with the approval of
he Institutional Review Board at Duke University;
ll patients provided written informed consent.
Image acquisition. CARDIAC MAGNETIC RESONANCE.
CMR was performed using 1.5-T scanners (Sie-
mens Sonata or Avanto, Siemens, Malvern, Penn-
sylvania). The pre-specified CMR protocol con-
sisted of two components: cine-CMR for
anatomical/functional assessment and DE-CMR
for tissue characterization. Cine-CMR used a
steady-state free-precession sequence (typical repe-
tition time: 3.0 ms; echo time: 1.5 ms; in-plane
spatial resolution: 1.7  1.4 mm; temporal resolu-
tion: 35 to 40 ms). DE-CMR, performed 10 to 30
min after gadolinium (0.15 mmol/kg) administra-
tion, used a segmented inversion-recovery sequence
(in-plane spatial resolution: 1.8  1.3 mm, tempo-
al resolution: 160 to 200 ms). Cine and DE-CMR
ere obtained in matching short- and long-axis
lanes (slice thickness: 6 mm). Short-axis images
ere acquired every 1 cm (gap: 4 mm) throughout
he entire LV. Long-axis images were obtained in
tandard 2-, 3-, and 4-chamber orientations.
On standard DE-CMR (tailored to null viable
yocardium; inversion time [TI]: 250 to 350 ms),
hrombus typically had an etched appearance (gray
entrally, black border) whereas viable myocardium
as black and infarcted myocardium white. As we
ave previously reported (18), the diagnosis of
hrombus by standard DE-CMR can sometimes be
hallenging as both viable myocardium and throm-
us appear relatively dark and are difficult to dis-
inguish from one another. Although contrast up-
ake is low in viable compared with infarcted
yocardium, it is not zero as is the case with
vascular tissue such as thrombus, and the differ-
nce in contrast uptake between viable myocardium
nd thrombus can be used to improve the conspi-
uity of thrombus. Thus, a tailored DE-CMR asequence was designed in which TI was increased
from that needed to null the viable myocardium
(250 to 350 ms) to a fixed time (600 ms) needed to
selectively null the avascular tissue such as thrombus
(21). With this long TI sequence, regions with
contrast uptake (i.e., LV cavity and myocardium)
appear bright, thrombus appears homogeneously
black, and there is improved thrombus delineation
(18).
ECHOCARDIOGRAPHY. Transthoracic 2-dimensional
chocardiograms were obtained by experienced sonogra-
hers on commercially available equipment (Sonos-5500
r 7500, Philips Healthcare, Andover, Massachusetts)
ith phased and sector array transducers. Echoes were
cquired in standard parasternal short- and long-axis as
ell as apical 2-, 3-, and 4-chamber imaging planes in
ccordance with American Society of Echocardiography
onsensus guidelines (22).
All echoes were performed as part of routine
linical practice; sonographer protocols were not
ltered for the current study. Echo contrast agents
perflutren lipid [Definity, Lantheus Medical Im-
ging, North Billerica, Massachusetts] or protein
Optison, GE Healthcare, Waukesha, Wisconsin]
icrospheres) were selectively used for cavity opaci-
cation and endocardial border delineation if
eemed clinically necessary at the time of imaging.
mages were digitally stored, viewed, and analyzed
sing Xcelera workstations (Philips Healthcare). In
ccordance with echo lab standards at our institu-
ion, images were displayed at a typical frame rate of
0 frames/s.
Data analysis. THROMBUS ASSESSMENT. Images
ere interpreted by consensus of two experienced
eaders (Level III trained in CMR and echo) who
ere blinded to subject identifiers, clinical history,
nd all prior imaging tests (CMR and echo). A
re-designated third reader was consulted in cases
f interpretive discordance (cine-CMR: 1%, DE-
MR: 4%, echo: 11%). Studies were read in ran-
om order. Each modality was interpreted indepen-
ently of the others.
For DE-CMR, thrombus was identified as an
V mass with post-contrast inversion-recovery
haracteristics consistent with avascular tissue
17,18). Thrombus appeared as a low-signal inten-
ity mass surrounded by high-signal intensity struc-
ures such as intracavitary blood and/or hyperen-
anced myocardial infarction on DE-CMR.
stablished criteria (21,23) were used to distinguish
hrombus from acute myocardial infarction with
icrovascular obstruction, which may also appear as
filling defect. Differentiating features included:
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7051) surrounding structures (no-reflow zones should
be completely encompassed by hyperenhanced
myocardium or LV cavity); 2) appearance (no-
reflow occurs within the myocardium and thrombus
in the LV cavity); and 3) stability of size on
consecutive DE-CMR acquisitions (no-reflow size
shrinks from contrast fill-in at the periphery,
thrombus size is stable). When thrombus was iden-
tified, morphology was classified as protuberant (if
borders were distinct from endocardial contours
with protrusion into LV cavity) or mural (borders
were contiguous with adjacent endocardial con-
tours) (24), with exams independently reinterpreted
to assess intrareader and inter-reader reproducibil-
ity. Thrombus volume was measured quantitatively
via planimetry. Thrombus location was scored
based on the nearest myocardial tissue using a
standard 17-segment LV model.
For echo and cine-CMR, thrombus was diag-
nosed using established anatomic criteria (25).
Thrombus was defined as a mass within the LV
cavity with margins distinct from ventricular endo-
cardium and distinguishable from papillary muscles,
chordae, trabeculations, or technical artifact.
Thrombus was diagnosed based on review of para-
sternal short- and long-axis images, and apical 2-,
3-, and 4-chamber images. Echoes interpreted as
positive for thrombus were scored for diagnostic
confidence on a 3-point scale (low, medium, high
confidence) based on clarity of thrombus definition
(distinct borders, independent mobility pattern)
and overall image quality (endocardial border defi-
nition, LV cavity artifacts).
LEFT VENTRICULAR QUANTIFICATION. LVEF and
LV volumes were quantified based on end-diastolic
and end-systolic endocardial contours from the
stack of short-axis cine-CMR images. Regional
wall motion and scarring were assessed on a stan-
dard 17-segment model using previously described
methods (26). Regional function on cine-CMR was
graded on a 5-point scale as follows: 0  normal
contraction; 1  mild-to-moderate hypokinesia;
2  severe hypokinesia; 3  akinesia; 4  dyski-
nesia. Regional scarring based on area of hyperen-
hanced (bright) myocardium on DE-CMR was
graded on a 5-point scale as follows: 0  no
hyperenhancement; 1  1% to 25%; 2  26% to
50%; 3  51% to 75%; 4  76% to 100%. Global
scar size as a percentage of LV myocardium was
calculated by summing the segmental scores (each
weighted by the midpoint of the range of hyperen-
hancement) and dividing by the total number of
regions (27). tStatistical methods. Continuous data (expressed as
ean  SD) were compared using 2-sampled t
ests. Non-normally distributed data (expressed as
edian and 25th to 75th percentiles) were com-
ared using the Wilcoxon rank sum test. Thrombus
olumes were compared after logarithmic transfor-
ation; results are expressed as the antilog of the
ean and 95% confidence intervals. Chi-square
ests were used to compare discrete data between
roups; in those cases where the expected cell count
as 5, Fisher exact test was used. McNemar test
as used for paired comparisons of discrete vari-
bles. All statistical tests were 2-tailed; p values
0.05 were regarded as significant.
R E S U L T S
Population characteristics. The study population
consisted of 243 patients who underwent routine
clinical echo and dedicated registry CMR within a
1 week (1.5 2.7 days) interval. The most common
clinical indications for echo were to assess LV
(92%) and/or valve (29%) function. Assessment
following CVA/TIA/systemic embolism was un-
common (2.5%; n  6), as was evaluation for
possible LVT (5%; n  13; known LV aneurysm/
apical dysfunction, n  5; prior documented LVT,
n  4; recent CVA, n  3; anterior myocardial
infarction, n  1).
Table 1 details patient characteristics, with com-
parison between the current study population and
registry patients. Patients with echo were relatively
similar to those without echo based on age, prior
thromboembolic events, and rates of warfarin use.
However, they were more often female and were
less likely to have prior coronary revascularization
and ischemic cardiomyopathy. Additionally, echo
patients were more likely to have advanced systolic
dysfunction as measured by LVEF or regional wall
motion score (both p  0.0001). Consistent with
this, prevalence of thrombus by DE-CMR was
slightly greater among the echo study population
versus registry patients who did not undergo echo-
cardiography (10% vs. 6%, p  0.04).
Follow-up validation. Follow-up was performed as
art of the registry protocol for endpoints supporting
he imaging diagnosis of thrombus (CVA, TIA,
athology verification). Of the 243 patients with
cho, 216 (89%) had complete follow-up for the
ntire 6 months after imaging. Patients with
ollow-up were similar to those without
ollow-up (n  27) based on prevalence of
hrombus by DE-CMR or echo, LVEF, or clin-
diac
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706ical indexes such as age, diabetes, or hypertension
(all p  NS).
Figure 1 shows the rate of study endpoints for
groups stratified by the presence or absence of
thrombus as determined by imaging. Previously
reported results of the overall registry are shown for
Table 1. Patient Characteristics
Parameter
Study Po
(n 
Clinical
Age, yrs 60
Male 63% (
Atherosclerosis risk factors
Diabetes mellitus 35% (
Hypertension 61% (
Tobacco use 24% (
Hypercholesterolemia 39% (
Prior myocardial infarction 44% (
Coronary revascularization 28% (
Percutaneous intervention 16% (
Coronary artery bypass grafting 17% (
Ischemic cardiomyopathy 63% (
Atrial ﬁbrillation 19% (
Lifetime history of prior cerebrovascular event
Cerebrovascular accident 9% (
Transient ischemic attack 7% (
Therapeutic regimen
Aspirin 58% (
Warfarin 14% (
Thienopyridines 6% (
Beta-blocker 51% (
ACE inhibitor 46% (
Angiotensin receptor blocker 6% (
Loop diuretic 31% (
Spironolactone 11% (
Digoxin 16% (
Nitroglycerin 28% (
Cardiac magnetic resonance
LV thrombus (DE-CMR) 10% (
LV function and morphology
Ejection fraction, % 28
Wall motion score 1.7
% LV with akinesis or dyskinesis 24% (
End-diastolic volume, ml 210
End-systolic volume, ml 156
Aneurysm present 16% (
LV infarction
Myocardial Infarction (presence) 71% (
Infarct size (% LV) 10% (
% LV with 50% transmural infarction 0% (
Values are mean  SD, % (n), or median (25th to 75th percentile). Numbers in
ACE  angiotensin-converting enzyme; DE-CMR  delayed enhancement carcomparison. For DE-CMR, patients with throm-bus had over a 5-fold higher rate of endpoints than
those without thrombus (16.7% vs. 3.1%, p 
0.02), a proportion similar to the7-fold difference
in the overall registry (18). There was a 1.8-fold
difference in endpoints when patents were stratified
by presence or absence of thrombus by echo (7.7%
ation
)
Registry Patients Without Echo
(n  541) p Value
61 14 0.86
74% (398) 0.004
26% (142) 0.009
59% (320) 0.57
29% (156) 0.15
57% (306) <0.0001
50% (269) 0.17
40% (268) <0.0001
31% (169) <0.0001
27% (147) 0.003
74% (401) 0.002
14% (74) 0.08
7% (37) 0.28
4% (22) 0.13
69% (371) 0.003
19% (101) 0.14
18% (98) <0.0001
71% (386) <0.0001
63% (343) <0.0001
13% (70) 0.005
45% (244) 0.0003
18% (96) 0.02
28% (150) 0.0004
18% (44) 0.004
6% (31) 0.04
33 10 <0.0001
1.5 0.7 <0.0001
) 24% (6–35) 0.054
206 85 0.50
142 79 0.03
12% (63) 0.12
75% (404) 0.25
) 16% (0–29) 0.03
) 12% (0–29) 0.002
dface indicate p values 0.05.
magnetic resonance; LV  left ventricular.pul
243
15
154)
86)
149)
58)
94)
108)
67)
39)
42)
154)
45)
22)
16)
140)
35)
16)
125)
111)
15)
76)
26)
39)
150)
24)
11
0.7
6–41
89
83
38)
172)
0–25
0–24
bolvs. 4.2%, p  0.34). Rate of endpoints was lower
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707among patients with thrombus by echo compared
with DE-CMR, despite the fact that patients with
thrombus by echo tended to be less likely to be
anticoagulated than were patients with thrombus by
DE-CMR (36% vs. 63%, p  0.054).
Prevalence of LVT. DE-CMR identified LVT in
10% (n  24) of patients, whereas echo was read
as positive in 12% (n  28). Despite similar
verall prevalence by echo and DE-CMR (p 
.5), there was substantial discordance between mo-
alities, as evidenced by the fact that only 8 patients
ad thrombus concordantly detected by echo and
E-CMR. Figure 2 provides a representative exam-
le of discordance between techniques, with echo read
s negative and DE-CMR read as positive in a patient
ith thrombus verified by pathology.
Echo contrast use. Echo contrast was administered
n 4% (n  10) of patients. Of the 10 patients who
eceived echo contrast, 2 had thrombus by DE-
MR and 8 were negative. Echo was negative for
hrombus in all 10 of these cases (accuracy 80%).
Diagnostic performance. Table 2 reports diagnostic
performance of echo and cine-CMR using the
reference of DE-CMR. Echo yielded a sensitivity
of 33% and specificity of 91%, and positive and
negative predictive values of 29% and 93%, respec-
Figure 1. Follow-Up Endpoints in Relation to Imaging Findings
Stratiﬁcation of patients with follow-up according to presence or ab
magnetic resonance (DE-CMR) yielded over a 5-fold difference in st
pathology-veriﬁed thrombus) between groups, whereas stratiﬁcatio
yielded a 1.8-fold difference (pink  thrombus , green  thrombtively. Although overall sensitivity and positivepredictive value were limited, echo performance
varied based on clinical indication, with sensitivity
increased more than 2-fold (60% vs. 26%) and
positive predictive value more than 3-fold (75% vs.
21%) for echoes performed for the clinical indica-
tion of LVT assessment compared with those per-
formed for nonthrombus indications.
Cine-CMR, which was acquired using a tailored
thrombus protocol and analyzed for thrombus using
the same criteria as echo, was used to provide
insight into echo performance by testing the degree
to which optimized anatomic imaging might influ-
ence diagnosis of LVT. As shown in Figure 3A,
echo sensitivity was 50% among cases in which
cine-CMR detected thrombus, whereas sensitivity
was only 10% in which cine-CMR missed throm-
bus (p  0.08). Regarding positive predictive value,
Figure 3B stratifies the diagnosis of thrombus first
by echo and then by cine-CMR. Among cases
where cine-CMR diagnosed thrombus, positive
predictive value of echo was 88%. When cine-CMR
was negative for thrombus, positive predictive value
of echo was 5% (p  0.0001).
Echo results also demonstrated that positive
predictive value was related to image quality/
diagnostic confidence. Echoes read for thrombus in
ce of left ventricular thrombus by delayed enhancement cardiac
endpoints (transient ischemic attack, cerebrovascular accident, or
cording to left ventricular thrombus by echocardiography (echo)
).sen
udy
n ac
us discordance with DE-CMR had lower diagnostic
2s
m
T
o
c
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708confidence scores (assigned at the time of blinded
interpretation) than echoes with concordant throm-
bus assessment to DE-CMR (1.95  0.69 vs.
.63  0.51, p  0.02).
Thrombus morphology. Among the 24 cases of DE-
CMR evidenced thrombus, 17 were classified as
protuberant and 7 as mural. Reproducibility was
high for both inter-reader (23 of 24) and intrareader
(23 of 24) classification of thrombus morphology
(kappa  0.90, 95% confidence interval: 0.69 to
1.0). Table 3 reports echo performance according to
thrombus morphology and size. As shown, echo
was far less likely to identify mural thrombus, with
nearly all protuberant thrombi detected (7 of 8; p
0.06). Improved detection of protuberant thrombus
occurred despite the fact that protuberant and
mural thrombi were, on average, virtually identical
in size (2.9 cm3). Further stratification demon-
Table 2. Thrombus Diagnosis by Routine Echo and Cine-CMR
Sensitivity Speciﬁcity
Echo (overall) 33% (8/24) 91% (199/219)
Clinical Indication
LVT 60% (3/5) 88% (7/8)
Other* 26% (5/19) 91% (192/211)
Cine-CMR (overall) 58% (14/24) 99% (218/219)
Values are % (n/N). *Excluding patients with echo done for stated indication o
Figure 2. Typical Example of LVT Assessment by Routine Echo a
(A) Routine echo demonstrates absence of thrombus but prominen
suboptimal image quality. (B) DE-CMR demonstrates a large mural
absence of apical thrombus. Note that thrombus on DE-CMR appea
ing. DE-CMR ﬁndings were conﬁrmed by direct surgical inspection
stain, high power) of surgically resected material, which demonstra
ﬁbrin content) adjacent to the LV anterior wall. LVT  left ventriculCMR  cardiac magnetic resonance; echo  echocardiography; LVT  left ventriculartrated that, for protuberant thrombus, size was a
ajor determinant of echo detection. As shown in
able 3, protuberant thrombi detected by echo were
ver 4-fold larger than those missed (6.6 vs. 1.3
m3, p  0.02). Echo performance paralleled that
of cine-CMR, for which detected protuberant
thrombi were over 6-fold larger than those missed
(4.9 vs. 0.8 cm3, p  0.01).
D I S C U S S I O N
Echocardiography is the most common cardiac
imaging test in the United States (15), with over 21
million exams performed annually (28). While the
utility of echo for the dedicated purpose of diag-
nosing LVT is established (3–5), echo is commonly
used as a general screening test and rarely per-
formed for the specific indication of LVT (10). We
ccuracy
Positive Predictive
Value
Negative Predictive
Value
(207/243) 29% (8/28) 93% (199/215)
(10/13) 75% (3/4) 78% (7/9)
(197/230) 21% (5/24) 93% (192/206)
(232/243) 93% (14/15) 96% (218/228)
sible LVT assessment (n  13).
Dedicated DE-CMR
ar-ﬁeld artifact within the left ventricular (LV) apex resulting in
mbus adherent to the LV anterior wall (asterisk) as well as
lack on long inversion time (TI) and etched on standard TI imag-
e LV and histopathology examination (C) (hematoxylin and eosin
a thrombus with organizing features (prominent collagen and
rombus; other abbreviations as in Figure 1.A
85%
77%
86%
95%
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709believe the current study is the first to assess
performance characteristics of routine echo for de-
tection of LVT. Major new findings include: 1)
how routine echo performs as a test for LVT in
context of everyday clinical practice; 2) factors that
influence LVT assessment, including fixed (i.e.,
thrombus morphology) and potentially modifiable
(i.e., image quality) indexes; and 3) magnitude of
improvement to be expected if echo protocols were
optimized for detection of LVT based on anatom-
ical appearance.
It is important to recognize that this study should
not be construed as an equivalent comparison between
diagnostic tests—echo versus DE-CMR. This would
require sonographic contrast use in all patients, a
strategy previously tested in our prior research (8). For
ur current study, DE-CMR was performed in a
edicated manner using tailored LVT imaging to
ake sure that our reference standard was optimized,
hereas echo was performed according to routine
linical practice. With this approach, we sought to
xamine current clinical practice patterns for echo and
o determine factors that influence echo performance
or assessment of LVT. One of the primary findings is
hat echo performance varied by indication for testing,
s evidenced by over a 2-fold higher sensitivity (60%
Figure 3. Imaging Results Concerning LVT
Echo results concerning the diagnosis of thrombus stratiﬁed by cin
Both echo sensitivity (A) and positive predictive value (B) were high
versus those in which cine-CMR was negative. Whereas cine-CMR ap
echo, both tests were negative in 9 of 24 patients with thrombus by Ds. 26%) and 3-fold higher positive predictive value(75% vs. 21%) among exams performed for the spe-
cific clinical indication of LVT.
In this real-life clinical cohort, echo contrast was
rarely used (4%). It is highly likely that echo perfor-
mance in this study would have substantially improved
were sonographic contrast used more frequently (6).
his low rate of echo contrast use is reflective of
d DE-CMR ﬁndings (pink  thrombus , green  thrombus ).
mong cases in which thrombus was also evidenced by cine-CMR
riately detected thrombus in an additional 7 patients with negative
MR tissue characterization. Abbreviations as in Figures 1 and 2.
Table 3. Thrombus Morphology in Relation to Echo Detection
LVT by DE-CMR (n  24)
Echo  (n  8) Echo – (n
Type
Protuberant 7 10
Mural 1 6*
Thrombus Size (cm3)
Thrombus Detected Thrombus
Echo
Overall 6.6 (2.0–21.4) 2.0 (1.2–
Protuberant thrombus 6.6 (2.0–21.4) 1.3 (0.8–
Cine-CMR
Overall 4.9 (2.6–9.3) 1.4 (0.6–
Protuberant thrombus 4.9 (2.2–11.0) 0.8 (0.5–
Indexes reported as antilog of mean (95% conﬁdence intervals) of log transf
boldface indicate p values 0.05. *In 1 case, DE-CMR detected mural thrombus
wall and excluded apical thrombus; echo was negative for anterior wall thromb
thrombus p value based on thrombus detection by correct location.e- an
er a
propp Value 16)
0.06
Missed
3.5) 0.054
2.3) 0.02
3.0) 0.02
1.1) <0.01
ormed data. Numbers in
adherent to mid anterior
us but positive for apicalAbbreviations as in Tables 1 and 2.
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710national practice patterns. In a recent multicenter
study encompassing over 4.3 million patients, echo
contrast was used in only 1.4% of exams (11). How-
ever, this study was a survey of a general population
and may not apply to our cohort of patients with
systolic dysfunction, in whom echo contrast may be
particularly useful for semi-quantitative evaluation of
LV systolic performance as well as LVT.
The importance of echo contrast is well estab-
lished. In prior research by our group among
patients at risk for thrombus (8), an obligate strat-
egy of echo contrast yielded nearly a 2-fold increase
in echo sensitivity (33% vs. 61%) for thrombus as
established by the reference standard of DE-CMR.
This concept was also demonstrated by Kurt et al.
(9), who studied patients with technically difficult
echo and reported that use of contrast excluded
thrombus in 34 of 35 patients in whom noncontrast
echo was positive while detecting thrombus in 5
additional patients in whom noncontrast echo was
negative. Whereas consensus guidelines recom-
mend that echo contrast be used in cases of subop-
timal image quality (22–29), low echo contrast
utilization rates persist despite the fact that 15% of
echoes without contrast have been reported to be
technically difficult (9) and up to 46% are inconclu-
sive for LVT (6). Our results demonstrate the im-
portance of diagnostic uncertainty concerning LVT.
Echoes that read positive for thrombus in discordance
with DE-CMR were assigned lower diagnostic con-
fidence scores than those that read in concordance
with DE-CMR (p  0.02). Taken together, these
findings demonstrate the importance of optimized
imaging protocols, including the frequent use of con-
trast, when echo is to be used to diagnose LVT.
To better elucidate the magnitude of improve-
ment in echo performance that could be expected if
imaging protocols were optimized, our analysis
included comparison of echo to cine-CMR—a test
that provides excellent endocardial border defini-
tion (30) while identifying thrombus using the same
anatomical criteria as echo. Echo results generally
tracked cine-CMR, with both echo sensitivity (p 
0.08) and positive predictive value (p  0.0001)
improved when limited to patients in whom cine-
CMR also detected thrombus. Cine-CMR did
identify thrombus in an additional 7 patients in
whom routine echo was negative, and it is likely
that echo would have also detected these if imaging
were tailored for optimized thrombus assessment.
On the other hand, even cine-CMR missed nearly
one-half (42%) of thrombi detected by DE-CMR,
suggesting that echo limitations are not modality-specific but are partially attributable to detection of
thrombus based on anatomic rather than tissue-
characteristic–based criteria. Regarding this point, it is
important to recognize that perfusion echo can be also
used for tissue characterization, and this approach has
been shown to be useful for assessment of thrombus
(31). Though promising, perfusion echo is not per-
formed as part of routine clinical practice at our center
and thus was not incorporated in the current study.
Stratification of thrombus detection based on
morphology and size demonstrated parallels be-
tween echo and cine-CMR. For both echo and
cine-CMR, protuberant thrombus was more likely
to be detected when large (p  0.02). Mural
thrombus was less likely to be detected by echo
irrespective of size (p  0.06), and this finding
paralleled results for the overall registry (18), in
which cine-CMR was shown to miss over half
(58%) of all mural thrombi detected by DE-CMR.
Our current findings extend results of prior
studies comparing echo to DE-CMR. Srichai et al.
(17), who studied patients with aneurysms under-
going LV reconstruction surgery, reported that
sensitivity of transthoracic echo for thrombus was
23% compared with 88% for CMR. All patients in
this study had pathology validation of the imaging
diagnosis of thrombus. However, in contradistinc-
tion to our study, all patients were at high pre-test
probability for LVT, imaging reports were retro-
spectively reviewed instead of primary interpreta-
tion of images, and neither cine-CMR nor DE-
CMR were analyzed as independent tests. Mollet et
al. (23) reported that the sensitivity of echo was
42% versus the reference of DE-CMR. However,
this study evaluated a small cohort of 57 patients
with CAD and no independent standard for throm-
bus was applied. In a separate study by our group
(8), conducted primarily among patients with acute
myocardial infarction, sensitivity of contrast echo
was 61%. However, these echoes were performed as
part of a research protocol that required obligate
sonographic contrast use in all patients.
A central aspect of our study concerns our use of
prospective follow-up to validate the imaging detec-
tion of LVT. Whereas dedicated DE-CMR yielded
over a 5-fold difference in endpoints between patients
with and without LVT (p  0.02), routine echo
yielded a 1.8-fold difference (p  0.34). Prior echo
studies have yielded conflicting results regarding the
clinical risks of LVT, with some reporting that throm-
bus does (32,33) and others that thrombus does not
(34,35) increase embolic event risk. Our results may
potentially explain the conflicting prior data, demon-
K
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711strating that although LVT is inherently associated
with increased thromboembolic event risk, this asso-
ciation may be missed if imaging is suboptimal. As
thrombus can be effectively treated with anticoagula-
tion, our findings regarding the clinical risks of throm-
bus and the importance of optimized imaging for
LVT assessment bear important clinical and thera-
peutic implications.
Study limitations. A limitation of our data concerns
the fact that although anticoagulation status was
obtained after imaging, long-term status was not
serially assessed throughout follow-up. It is possible
that the timing and intensity of warfarin treatment
may have been suboptimal in some patients with
LVT, and this may have influenced the risk for
thromboembolic events.
C O N C L U S I O N S
In summary, our study provides new data concern-
ing routine clinical echo as a screening test for
LVT. Among this diverse cohort of patients with
systolic dysfunction, routine echo with rare use of
contrast often yielded misleading results concerning
presence or absence of thrombus. Echo performance
improved when imaging was performed for the spe-
cific indication of LVT. Diagnostic performance ofvalidation. Chest 1983;83:228–32. sue characterizationity and positive predictive value among patients in
which cine-CMR was positive for thrombus. Like
cine-CMR, echo was less likely to detect protuberant
thrombus when small, although mural thrombus was
frequently missed independent of size.
The results of this study add to a growing body of
literature that has demonstrated the utility of DE-
CMR for LVT assessment in high-risk popula-
tions, such as individuals with advanced LV systolic
dysfunction, aneurysms, and/or large myocardial
infarctions. A dedicated DE-CMR protocol, in-
cluding use of long-TI imaging, could be used to
confirm the diagnosis of LVT by routine echo in
cases when diagnostic confidence is low or sono-
graphic contrast use is not used. However, these
findings should be confirmed by other groups be-
fore recommending broad changes in practice pat-
terns regarding imaging for LVT. Future research is
also necessary to compare the relative utility of
dedicated thrombus imaging by tailored echo and
DE-CMR for prognostic assessment and therapeu-
tic management of patients at risk for LVT.
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